title: Fewer recurrent infections of C. difficile seen with fidaxomicin. This new class of antibiotic--the macrocycles--has a greater sustained response against re-infection than vancomycin.
authors.affiliation: Genentech, USA. TMorrow@ManagedCareMag.com
authors.forename: Thomas
authors.initials: T
authors.lastname: Morrow
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016360:Clostridioides difficile / Q000187:drug effects* / Q000472:pathogenicity; D003015:Clostridium Infections / Q000188:drug therapy* / Q000191:economics; D057186:Comparative Effectiveness Research; D003362:Cost-Benefit Analysis; D000077732:Fidaxomicin; D006801:Humans; D055502:Secondary Prevention; D014640:Vancomycin / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D014640:Vancomycin; D000077732:Fidaxomicin